Business Wire

TX-FLUENCE-BY-OSRAM

Share
Fluence Partners with White Lion Holdings to Provide Crucial LED Lighting Solutions in Developing South African Commercial Cannabis Market

Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today it has partnered with White Lion Holdings , the leading consultant providing complete solutions for new and aspiring cannabis growers in South Africa.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211123005520/en/

Fluence’s South African partners include local distributor The Lamphouse, the largest supplier of specialized lamps in Africa with more than 40 years of experience in numerous specialty lighting sectors, and White Lion Holdings, a company offering complete cannabis growing solutions and consultancy, led by CEO Cornel van der Watt. Van der Watt has served at the forefront of developing cannabis markets in the U.S., Canada, the Netherlands and Lesotho, and has consulted extensively in Australia.

“Local partnerships are a key factor in delivering fast and reliable solutions to growers. Our stellar partners know the choice of lighting supplier is crucial to delivering consistent, high-quality yields premium clients in the northern hemisphere require,” said Timo Bongartz, Fluence’s general manager for Europe, the Middle East and Africa (EMEA). “Van der Watt chose to partner with Fluence and our local partner The Lamphouse based on his experience with Fluence’s superior LED products and valuable support in various jurisdictions where he has historically consulted cannabis growers.”

According to Prohibition Partners’ African Cannabis Report™ , by 2023, Africa’s legal cannabis industry could be worth more than $7.1 billion annually, with South Africa alone contributing an estimated $1.7 billion per year. The South African government’s recognition of the industry as a key to economic revival mirrors Prohibition Partners’ assessment—the cannabis industry represents the potential to create between 10,000 -25,000 job opportunities in a country with the highest unemployment rate in the world.

“The African cannabis market holds incredible potential and we know we’ve found the right partner in White Lion Holdings. We’re proud to collaborate with such a trusted brand and to support the growers who are revolutionizing the South African cannabis market,” Bongartz continues.

As the cannabis industry continues to gain traction throughout the country and continent, White Lion Holdings suggests growers will not only need innovative technology at their fingertips, but evidence-backed cultivation practices that yield high-quality crops, improved yields and consistent growth patterns.

“We’re thrilled to partner with Fluence and its local partner The Lamphouse,” said Van der Watt, who is currently consulting and managing four commercial operations throughout South Africa with other operations in the pipeline. “The cannabis plant is highly photosensitive. We prefer natural lighting and South Africa has an advantage in this regard with ample, good quality natural light. By choosing the location of the greenhouse well, one can get up to 11 hours of natural light for free. Then, we integrate supplemental lighting into the facility to optimize crop yield.”

The South African market is still in its infancy. Through its partnership with White Lion Holdings, Fluence lighting solutions have been implemented at pre-licensed and licensed cannabis greenhouse and indoor facilities throughout the country.

“I am testing various lighting solutions all the time, but those tests only reaffirm my partnership with Fluence and its local partner The Lamphouse given each company’s superior quality and valuable support. Thanks to consistent lighting, I have been able to surpass production targets. That is only possible with superior lighting,” Van der Watt added.

To achieve longevity in an industry that can quickly become crowded with new technologies and cultivation solutions, investors and growers must ensure they partner with experts in their respective fields who are purpose-built to support cultivators for the long-term.

“The Fluence system all but eliminates lighting as a variable and delivers a high return on investment. Optimizing the correct lighting strategy for the correct application and layout is one of the critical components to successful crop,” said Glenn Morris, CEO of The Lamphouse.

For more information on Fluence, visit www.fluence.science .

About Fluence by OSRAM

Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM, creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit www.fluence.science .

About Cornel van der Watt and White Lion Holdings

With over 29 years of international, large scale cannabis cultivation experience under his belt, the White Lion Cornel van der Watt is in a class of his own. His knowledge of all aspects of the cannabis industry and his connections in the global cannabis community are unparalleled. He has also been at the forefront of the cannabis movement in South Africa since inception.

Every path he has walked in his professional and personal life has led him back to the cannabis industry. This path traces back to his qualification in chemical engineering, experience in scientific glassblowing, expertise in cultivation abroad and locally, studies in tissue cultivation, cloning and genetics, his community upliftment work as well as training and consulting.

While Cornel has become a scientist, a geneticist, a businessman and Cannabis Supremo, at the heart of his consultancy lies a deep and spiritual connection with the cannabis plant. For more information about White Lion Holding, visit https://www.whitelionholdings.co.za .

About The Lamphouse

Established in 1976, The Lamphouse is the largest supplier and distributor of specialized lamps in Southern Africa. Over the past 40 years, The Lamphouse has developed strategic relationships with suppliers and customers alike, providing lighting applications for horticulture, medical solutions, stage and studio, airfield, navigation and more. The company is headquartered in Johannesburg, South Africa, with additional offices in Cape Town and Durban. For more information about The Lamphouse, visit https://www.thelamphouse.co.za .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 14:00:00 CET | Press release

Fundamental Cure for Intractable and Incurable Diseases using ‘Biological Age Zero’ Cells Derived from Patient’s Own Cells via SCNT TechnologyWorld's First Therapy Platform Simultaneously Solving Immune Rejection and Inheritance of Cellular Aging—The Major Hurdles of Existing Stem Cell TherapiesDrastically Improving Treatment Accessibility through the New Paradigm, ‘Patient-Initiated Clinical Trial™’, which Overcomes Existing Clinical Limitations Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evalu

HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release

Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 13:30:00 CET | Press release

- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line diffuse large B-cell lymphoma (DLBCL) in the first half of 2026 Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years o

SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance witha Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 13:00:00 CET | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 13:00:00 CET | Press release

Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved Pre-Specified Patient Reported Outcome Measures Data Underscore the Potential to Shift the Treatment Paradigm for PV Patients to Reduce the Burden of Frequent Phlebotomies and Meaningfully Improve Hematocrit Control Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell product

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye